Beclorex

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Beclorex

What is Beclorex? An Overview

Beclorex is a trade name for the active substance Beclometasone, a potent synthetic steroidal drug primarily designed to reduce inflammation in specific body areas. It belongs to the class of glucocorticoids, which defines its strong action in calming overactive inflammatory responses. The medication is widely clinically recognized for its efficacy in the long-term management of conditions characterized by persistent inflammation of the airways and nasal passages.

Property Description
Active ingredient Beclometasone (INN)
Form Inhalers (MDI/DPI), Aqueous Nasal Spray
Pharmacological class Corticosteroid (Glucocorticoid)
General purpose Long-term control of chronic inflammation
Origin Synthetic steroidal compound

What Type of Medicine is Beclorex and What is its Composition?

Beclorex is a glucocorticoid medicine, meaning its structure is chemically similar to natural steroid hormones, giving it the ability to manage chronic inflammation. Its active compound is Beclometasone, typically administered as the prodrug Beclometasone dipropionate. The prodrug status is a key differentiating feature, ensuring the substance is chemically inactive until converted into the highly potent active form at the target site. This drug is entirely synthetic in origin and is generally formulated as a single-ingredient product, offering specialized, targeted anti-inflammatory action.


What are the Primary Forms of Beclorex?

The primary forms of Beclorex are optimized for localized delivery, notably the inhaler (metered-dose or dry powder) and the aqueous nasal spray. These specialized preparations ensure the drug is administered directly to the site of irritation, such as the bronchial airways (via inhalation) or the nasal lining (via intranasal use). This strategy of targeted application maximizes the drug’s effectiveness where needed while minimizing systemic exposure, which is particularly beneficial for the pediatric patient groups for whom Beclometasone is commonly prescribed.


What is the General Purpose of This Glucocorticoid?

The general purpose of this glucocorticoid is to provide long-term prevention and control of chronic inflammatory conditions by modulating the local immune response. Beclometasone acts as a potent anti-inflammatory agent by calming the underlying tissue reactivity, which effectively helps to sustain normal function over time. For example, it is typically used to manage persistent nasal inflammation, preventing discomfort and congestion from returning.

What side effects are possible with Beclorex?

Possible Side Effects and Safety Information

The official safety documentation for Beclorex (Beclometasone) outlines adverse reactions based on frequency and affected body systems, derived strictly from governmental regulatory sources. The most common adverse reactions generally involve the upper respiratory tract, classified in the regulatory labeling as Infections and Infestations, and Respiratory, Thoracic, and Mediastinal Disorders.

Commonly reported effects include Headache, Pharyngitis (sore throat), Upper Respiratory Tract Infection, and localized reactions such as Oropharyngeal Candidiasis (thrush) and Dysphonia (hoarseness).


Clinically Significant Safety Considerations

Certain adverse reactions are documented as clinically significant or rare events. These include an immediate, acute reaction called Paradoxical Bronchospasm, and serious Hypersensitivity Reactions such as Angioedema. The medicine is contraindicated for the primary treatment of acute, severe episodes like Status Asthmaticus.


Safety Patterns Linked to Duration and Population

Regulatory documents highlight that the potential for systemic effects is associated with long-term or prolonged use, specifically citing risks related to the Endocrine System (Adrenal Suppression) and Eye Disorders (Glaucoma or Cataracts).

Population-specific safety statements are provided for certain groups. In pediatric patients, the label notes the potential for a reduction in growth velocity, requiring clinical monitoring. For COPD patients, an increased incidence of Pneumonia has been observed and documented in the official safety profile.

Overdose and Emergency Response

Overdose and when to seek help

The official overdose profile for Beclorex primarily distinguishes between acute and chronic overexposure. Regulatory documentation indicates that an acute, single-event overdose is generally not expected to cause immediate systemic issues requiring intervention.

Documented Overdose Presentations

Manifestations of overexposure are instead linked to chronic, excessive dosing and may lead to signs of Hypercorticism or Adrenal Suppression (Hypoadrenalism). Documented symptoms of these systemic effects include unusual tiredness, muscle weakness, and a puffy appearance of the face.

Focus Area Official Regulatory Note
Systemic Effects Suppression of the endocrine system and potential imbalances in fluid/electrolytes.
Pediatric Risk Prolonged use of high doses in children is associated with a risk of slowing of normal growth.
Management Treatment is strictly symptomatic and supportive, often requiring continuous monitoring of vital signs and laboratory values (e.g., blood sugar and potassium levels).

When Immediate Medical Help is Required

If overdose is suspected, immediate medical attention is required; individuals should contact a poison control center or emergency department immediately. Urgent medical assistance must also be sought for any signs of a severe immediate reaction, such as swelling of the face, tongue, or throat, or difficulty breathing, as these can indicate a life-threatening complication.

Therapeutic Uses of Beclorex

Beclorex is considered relevant for easing symptoms that interfere with daily functioning and create noticeable physiological strain, generally across three key domains. The medication is relevant for easing symptoms of increased neurological or muscular activity, which often cluster as muscle-related symptoms, consistent with guidelines for symptomatic support.

The medication is commonly used to help with conditions involving episodic or fluctuating manifestations, including intense muscle spasms, symptoms of significant dermatologic inflammation, and heightened airway constriction. It is applied in scenarios where additional symptomatic support is needed, assisting with the temporary management of symptoms related to physical discomfort.

Relief and Core Therapeutic Domains

Beclorex helps address symptom clusters that may become intense or disruptive, contributing to improved comfort during periods of heightened symptoms. The medication plays a role in managing conditions associated with acute or disruptive episodes. This assistance is considered appropriate when symptoms create noticeable physiological strain. It helps maintain a sense of stability when symptoms are more noticeable, supporting general well-being during symptomatic phases.

Quick Fact

Quick Fact: Supports Management of Spasm Discomfort

Beclorex is used for managing symptoms of increased neurological or muscular activity, applied in clinical settings that involve acute or unstable symptom patterns.

Regulatory References

  1. Label: BACLOFEN tablet - DailyMed

Eligibility and Restrictions for Use

Beclorex eligibility is strictly defined by regulatory bodies based on age, acute disease status, and specific comorbidities. It is established for the maintenance treatment of asthma in adults, adolescents, and children beginning at age four or five, depending on the specific product formulation. Safety and efficacy are not established for children below this minimum age, and long-term use in pediatrics necessitates the monitoring of growth velocity, as required by official documentation.

Absolute Non-Eligibility (Contraindications)

The medicine is contraindicated for any patient with a known hypersensitivity to Beclometasone dipropionate or any of its excipients. Beclorex is not indicated for the relief of acute bronchospasm or status asthmaticus; its use is restricted to routine long-term management.

Conditional Use (Restricted Populations)

Use is conditional and requires caution in certain populations. This applies to patients with severe hepatic or severe renal impairment; in these cases, use is only permitted if the expected benefit outweighs the potential risk. Caution is also mandated for patients with active or quiescent infections, such as tuberculosis or ocular herpes simplex. For pregnant or breastfeeding individuals, use is conditional, requiring a regulatory determination that the maternal benefit justifies the potential hazard to the infant or fetus.

What should I know about interactions with other medicines?

Interaction Map: Interactions with other medicines and products — official regulatory information for Beclorex

Interaction Scope

Category Official Regulatory Documentation
Medicinal product categories with documented interactions Strong CYP3A4 Inhibitors; Other Systemic Corticosteroids
Specific interacting medicines (if explicitly listed) Ritonavir
Mechanistic basis of interactions (only if stated in label) Pharmacokinetic interaction (inhibition of CYP3A4-mediated clearance of active metabolite); Pharmacodynamic interaction (additive effects)
Timing-based interaction rules (if applicable) None documented as a mandatory requirement in the regulatory labels reviewed.
Population-specific interaction notes (if applicable) Caution noted for patients with Hepatic Impairment, due to the potential for reduced clearance and accumulation.
Interaction-related restrictions None documented as a formal contraindication based on interaction risk.

Interaction Classifications (High-Level)

Classification Type Official Regulatory Documentation
Interaction severity classification (as defined in official documents) Clinically significant (exposure-altering pharmacokinetic interaction) and potential for additive effect (pharmacodynamic interaction)
Regulatory basis (EMA / FDA / etc.) Information derived from FDA Prescribing Information and EMA/SmPC data
Interaction-context constraints (as defined in official documents) Interaction with CYP3A4 inhibitors is tied to the metabolism of the active metabolite (17-BMP), not the parent prodrug.

Resulting Interaction Structure

Official interaction statements:

  • Co-administration with strong CYP3A4 inhibitors results in a pharmacokinetic interaction due to reduced clearance of the active metabolite, Beclometasone-17-monopropionate (17-BMP).
  • The strong CYP3A4 inhibitor Ritonavir has been shown to increase the systemic exposure (AUC and Cmax) of the active metabolite, 17-BMP, according to regulatory data.
  • There is a documented pharmacodynamic interaction risk involving an additive effect on the HPA-axis when co-administered with other systemic corticosteroids.
  • A population-specific note acknowledges that hepatic impairment may reduce the clearance of the corticosteroid, leading to a risk of accumulation.

Connection to the overall interaction profile (2–4 sentences):

The regulatory interaction profile for Beclorex is structured around two primary concerns: pharmacokinetic modification due to its reliance on CYP3A4 for clearance of the active metabolite, and a pharmacodynamic risk of additive HPA-axis suppression with other steroids. The official documents identify strong CYP3A4 inhibitors as the key interacting substance class, citing data from co-administration studies. The profile is further constrained by the physiological status of the patient, specifically noting reduced clearance in the context of hepatic impairment.

Mechanism of Action

Genetic Control: Receptor Activation and Gene Modulation

The mechanism begins when the active compound, Beclometasone 17-monopropionate, acts as an agonist on the Glucocorticoid Receptor (GR), initiating its movement into the cell nucleus. This activated complex then simultaneously upregulates the expression of anti-inflammatory genes and represses the activity of key pro-inflammatory transcription factors like NF-kappaB. This core action modulates the cellular genetic program, leading to changes in inflammatory protein synthesis.


Cascade Termination and Eicosanoid Blockade

A direct consequence of this genetic modulation is the increased synthesis of Lipocortin-1 (Annexin A1), a protein that inhibits Phospholipase A2. This blockade terminates the eicosanoid synthesis pathway, reducing the production of inflammatory mediators such as prostaglandins and leukotrienes. This cascade termination, combined with the suppressed infiltration and activity of immune cells like eosinophils, produces the physiological consequence of reduced mucosal edema and decreased tissue responsiveness at the application site.

Dosage and Administration Information

Official Administration Guidelines (Bromhexine Hydrochloride)

These instructions outline the standardized usage of the medicine, based on established specifications for products containing the active ingredient Bromhexine hydrochloride. Products are available for oral use as liquid or tablet dosage forms.

Dosing and Frequency

Age Group Single Dose Range Dose Interval Maximum Daily Dose
Adults & Children 12+ years 8 mg to 16 mg Every 8 hours as necessary 3 doses
Children 6–11 years 8 mg Every 8 hours as necessary 3 doses

Administration Rules

  • Route: The medicine is administered orally (by mouth).
  • Oral Liquid Preparation: If using the oral liquid form, the correct volume must be accurately measured to ensure the prescribed dose (e.g., 8 mg or 16 mg equivalent) is taken.
  • Soluble Tablets: Soluble tablets, if used, should be allowed to dissolve fully before swallowing.
  • Administration Timing: The dose should be taken every 8 hours, only as necessary, and must not exceed the maximum daily dose of three administrations within a 24-hour period.
  • Age Restrictions: Do not administer this medicine to children under 6 years of age. Use in children aged 6 to 11 years should only occur on the advice of a medical professional, such as a doctor, pharmacist, or nurse practitioner.

Recent Clinical Evidence

Research evidence / Overview of studies for Beclorex


Evidence for use in Asthma Maintenance Treatment

Research has primarily utilized Randomized Controlled Trials (RCTs) and systematic reviews to explore how Beclorex was evaluated in research for the management of persistent airway inflammation. These studies were applied in research contexts involving fluctuating or unstable symptoms, including populations ranging from adults to children across various age groups. Researchers examined how the medicine was studied for functional measures like FEV1 (a measure of lung function) and Peak Expiratory Flow (PEF). Outcomes reflecting daily functioning or activity level were also monitored.

Studies reported measured changes in lung function values in subjects receiving the study medicine compared to placebo arms over defined time intervals. Research highlights changes measured during the study period concerning the need for rescue bronchodilators, with data showing patterns related to changes in the need for rescue short-acting beta2-agonist medication. What remains uncertain is the full profile of long-term outcomes beyond the initial 6-to-12-week trials; these long-term outcomes are not fully established. Research provides context but not individual predictions.


Evidence for use in Allergic and Vasomotor Rhinitis

For the nasal spray formulation, the evidence base mainly relies on placebo-controlled, double-blind RCTs that research examined across both seasonal and perennial allergic rhinitis. These trials were relevant in evidence describing how symptoms are measured, focusing on the Total Nasal Symptom Score (TNSS), which monitors outcomes such as nasal congestion, sneezing, and itching. Research has explored the medicine’s role in conditions involving periods of heightened symptoms and included adults, adolescents, and children in its study populations.

Studies report how symptoms evolved in the observed populations, describing statistically measured changes in the TNSS scores among the populations receiving the study medicine over the typical 6-to-12-week treatment period. The evidence also contributes to understanding symptom patterns by monitoring patterns related to changes in subject-reported quality of life. Long-term outcomes are not fully established regarding the durability of the effect if treatment is used only intermittently across multiple years.


The Landscape of Research Uncertainty

One key limitation is that the evidence quality varies across studies, especially those designed to compare Beclorex with other existing medicines; comparative evidence is limited in some areas. Research notes that the study design had to account for the variability introduced by user technique, a factor that researchers monitored differently across various clinical settings. For many systemic outcomes that require long observation periods, long-term outcomes are not fully established, and research is ongoing to fully characterize the medicine's profile across all potential risk and patient groups.

Frequently Asked Questions (FAQ)

Common questions about Beclorex (FAQ)


Q: How quickly does Beclorex usually start to work?

Studies and official information indicate that Beclorex is not intended for immediate relief. For the maintenance of conditions like asthma, patients may typically notice an improvement in lung function within one to four weeks after regular use begins. If used in the nasal form, full benefits may take one to two weeks, though some initial improvement might be noticed sooner.


Q: How long can a person typically expect to use Beclorex?

Regulatory documents describe Beclorex as a maintenance treatment intended for the long-term control of chronic inflammation. This indicates the medicine is designed to be used regularly over an extended period for symptom prevention. Patients should not suddenly stop using the medicine without consulting their healthcare provider, as symptoms may return or worsen.


Q: Do children or elderly people use Beclorex differently?

Official product information often specifies different dosing schedules or requirements for children compared to adults, including the elderly. For example, specific maximum daily doses are established for pediatric patients. Unless there are other underlying health conditions, no specific dose adjustment is typically needed for individuals aged 65 years and older.


Q: Can Beclorex be used by someone who is pregnant or breastfeeding?

Official guidance states that the use of Beclorex during pregnancy or breastfeeding is conditional. The decision to use the medicine is based on a determination by a healthcare professional after assessing whether the potential benefit to the mother justifies any potential hazard to the fetus or infant. Regulatory documents state that patients should inform their healthcare provider about pregnancy or planning to breastfeed.


Q: What evidence supports the use of Beclorex in the long term?

Beclorex is officially indicated for maintenance (long-term control), a use supported by clinical trial data that shows sustained improvement over the initial study periods, typically lasting 6 to 12 weeks. While these trials provide the basis for its maintenance indication, regulatory documents note that the full characterization of long-term outcomes beyond these initial trial durations is ongoing.


Q: Can people with liver problems use Beclorex?

Regulatory documents advise caution for individuals with severe hepatic impairment (severe liver problems). This is due to the potential for the body to clear the active substance more slowly, which could lead to an accumulation of the medicine over time. The status of caution is noted in regulatory information for these populations, indicating conditional use.


Q: Can people with kidney issues use Beclorex?

Caution is generally required for patients who have severe renal impairment (severe kidney issues), as noted in official regulatory information. For these conditional populations, regulatory caution applies, and the decision to use the medicine involves an assessment of whether the expected benefit outweighs the potential risks.


Q: Is Beclorex a controlled substance or habit-forming?

According to official sources, Beclorex is not classified as a controlled substance by agencies like the U.S. Drug Enforcement Administration. Furthermore, the medicine is not known to be habit-forming or associated with dependence.


Q: What happens when Beclorex is stopped?

Regulatory information indicates that abrupt discontinuation of Beclorex is not recommended. Stopping the medicine suddenly can potentially cause underlying symptoms to return or worsen. If the medicine needs to be stopped, it should be done under the guidance of a healthcare professional.


Q: Is there a known link between Beclorex and weight changes?

Official safety documents list adverse reactions based on frequency, but weight gain or weight changes are not consistently listed among the common or frequent side effects reported for the standard inhaled forms of Beclorex.


Q: Does Beclorex cause drowsiness or affect driving?

Regulatory safety documents for Beclorex do not typically list drowsiness or effects on the central nervous system as a common or frequent adverse reaction. Official documents do not typically specify that the medicine impairs a person’s ability to drive or operate machinery.


Q: Are there any food or drink restrictions while using Beclorex?

Official regulatory summaries primarily detail interactions with other medicines. Food or drink restrictions, such as mandatory prohibitions against common foods or alcohol, are generally not specified as a required warning or contraindication in the product labels.


Q: What happens if I miss a scheduled time to use Beclorex?

Official drug information sources state that if a regular dose is missed, it should generally be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped entirely, and the regular schedule should be resumed. Patients should not attempt to take a double amount to make up for the missed one.


Q: Are there any lifestyle changes that are often discussed along with Beclorex?

Patient guidance often highlights the importance of managing factors that may worsen the underlying condition. For example, managing factors like smoking is often discussed, as official data suggests that smoking can potentially reduce the medicine’s effectiveness and worsen the condition being treated.


Q: Why do official documents mention specific tests are needed before starting Beclorex?

Regulatory documents mention that, before starting treatment, tests may be needed to check for the presence of certain active or quiescent infections. Corticosteroids like Beclorex can potentially affect the body's response to infections, such as tuberculosis, so these conditions must be assessed beforehand.


Q: Does Beclorex interact with herbal supplements?

Official interaction lists focus on specific drug classes and substances but do not typically name all herbal supplements. Because of the potential for unknown interactions, official guidance often advises patients to fully inform their healthcare team about all medicines and supplements they use, including herbal products.


Q: What happens if I use Beclorex for longer than intended?

Official regulatory warnings state that using the medicine for prolonged periods or exceeding recommended doses increases the risk of certain systemic effects. These potential effects include impacts on the adrenal gland function (adrenal suppression) and risks of certain eye disorders, such as cataracts or glaucoma.


Q: How should I prepare for a doctor's visit to discuss Beclorex?

Preparation, according to patient guidance, typically involves gathering information about all current and past medical conditions, especially infections. It also involves informing the healthcare provider about every medicine or supplement currently being taken, and clarifying if you are pregnant, trying to conceive, or breastfeeding.


Q: What happens if I accidentally take two amounts of Beclorex close together?

Taking more than the prescribed amount close together may temporarily suppress the adrenal gland function (known as HPA-axis suppression). Regulatory documents state that patients should contact their healthcare provider immediately for guidance in the event of any accidental overdose or misuse.


Q: What does the patient information leaflet say about Beclorex?

The official Patient Information Leaflet (PIL) provides comprehensive instructions on the use of the medicine, including how it works, how to properly administer it, known side effects, and important warnings. It highlights the medicine's role as a preventer and emphasizes the need for regular use to maintain control.


Q: Are there any specific laboratory tests that are affected by Beclorex?

Official studies monitor HPA-axis function (e.g., cortisol levels) to assess for potential systemic effects of the medicine. However, regulatory reviews often note that there were typically no significant changes in standard clinical laboratory tests reported during the studies.

How should Beclorex be stored and disposed of?

How to Store and Dispose of Beclorex

Beclorex (beclomethasone dipropionate) must be stored at room temperature, typically between 20 C and 25 C, and not above 30 C. It is mandatory to keep the medication out of the sight and reach of children.

Storage Requirements

The product must be protected from freezing, heat, and direct light, and should be kept in its original container with the cap tightly closed. The inhaler canister must never be punctured or thrown into a fire, even when empty.

Disposal Instructions

Discard Beclorex when the dose counter displays zero or after the expiration date. Medicines should not be disposed of via wastewater or household trash. Patients must consult a healthcare professional for guidance on returning unused or expired product to an approved collection program, following local regulatory guidelines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Beclorex found in:

A-Z Index: